About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 245 record(s)
Req # A-2021-000607
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-113074-49.Organization: Health Canada
August 2022
Req # A-2021-000674
Adverse Drug Reactions (ADRs) for FLUDARABINE PHOSPHATE. Report numbers: 000919535, E2B_03441213, E2B_03309030, E2B_03448428, 918900, 918925, E2B_03504815, E2B_03311993, 000926195, 918889, E2B_03281693, E2B_03278638, E2B_03397991, 924865, 921884, 920455, 918911, E2B_03442250, 920444, 000918874, 918905.Organization: Health Canada
August 2022
Req # A-2021-000842
Adverse Drug Reactions (ADRs) for METRONIDAZOLE. Report numbers: E2B_03503629, E2B_03402287, E2B_03501611, E2B_03501655, E2B_02825695, E2B_03502061, E2B_03500749, 000923297, E2B_03519477, 000927809, 000920656, E2B_03497091, E2B_03500088.Organization: Health Canada
August 2022
Req # A-2021-000875
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03295833, 000926661, 2020223625, 000921367, E2B_03328973, E2B_03286399, E2B_03367537, E2B_03371330, 000929140, E2B_03326192, E2B_03278656, E2B_03279144, E2B_03292372, E2B_03363709, E2B_03376228, E2B_03325739, E2B_03388763, 000926537, 000926525, 000926513.Organization: Health Canada
August 2022
Req # A-2021-001259
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: 939340, 939359, 000945375, E2B_01812502, 000944427, E2B_01812413, 000719986, 000945584, E2B_04002643, E2B_04005601.Organization: Health Canada
August 2022
Req # A-2021-001497
Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_04484269, E2B_04494416, E2B_04460249, E2B_04432576, E2B_04363203, E2B_04462295, E2B_04436295, E2B_04404907, E2B_04432594, E2B_04449163, E2B_04414170, E2B_04417110, E2B_04413887, E2B_04402351, E2B_04470225, E2B_04441940, E2B_04463453. ADRs for VYVANSE. Report numbers: E2B_04492112, 000958293.Organization: Health Canada
August 2022
Req # A-2021-001588
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03674880, E2B_03747050, 000952974, E2B_04079115, 000938774, E2B_03664485, E2B_04079113, E2B_03980283, E2B_04031988, E2B_03930706, E2B_04079523, 000954990, 000930359, E2B_04036473, E2B_03956154, E2B_03753033, E2B_03720550, E2B_03813988.Organization: Health Canada
August 2022
Req # A-2021-001714
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-118769-401.Organization: Health Canada
August 2022
Req # A-2021-001793
Adverse Drug Reactions (ADRs) for RANITIDINE HYDROCHLORIDE. Report numbers: E2B_04399699, E2B_04472034, E2B_04399611, E2B_04436987, E2B_04375028, E2B_04238483, E2B_04540427, E2B_04543353, E2B_04147422, E2B_04347890.Organization: Health Canada
August 2022
Req # A-2021-001794
Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: E2B_04404194, E2B_04219248, E2B_04446477, E2B_04177090, 000959819, 000956920, 000961963, E2B_04118819, 000969044, E2B_04328989, E2B_04115914, 000970239, E2B_04410041, E2B_04398048.Organization: Health Canada
August 2022